Finoriq research workspace
Propanc Biopharma, Inc. (PPCB) SEC Filings & Filing Highlights
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the. Review PPCB SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.
- Company
- Propanc Biopharma, Inc. (PPCB)
- Ticker
- PPCB
- Market Cap
- $3.2M
- Latest Price
- $1.39
- Industry
- Biotech & Pharma
Propanc Biopharma, Inc. (PPCB) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Propanc Biopharma, Inc. (PPCB).
| Event | Form | Date |
|---|---|---|
| Effective February 20, 2026, Dr. Julian Kenyon retired and stepped down from the Board of Direc...Effective February 20, 2026, Dr. Julian Kenyon retired and stepped down from the Board of Directors (the “Board”) of Propanc Biopharma, Inc... | 8-K5.02 | 2026-02-26 |
| Disclosure Regarding Forward-Looking InformationOn December 31, 2025, Propanc Biopharma, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Depa... | 8-K3.01 | 2026-01-07 |
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearAmendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 8-K5.03 | 2025-11-10 |
| Propanc Biopharma, Inc.: Securities issuanceAs previously disclosed in our Current Report on Form 8-K filed with the Securities and Exchange Commission on October 14, 2025, on October... | 8-K3.02 | 2025-11-10 |
| Propanc Biopharma, Inc.: Material agreementOn October 7, 2025, Propanc Biopharma., Inc. (the “Company”) entered into a Securities Purchase Agreement (the “SPA”) with Hexstone Capital... | 8-K1.01 | 2025-10-14 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.